Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
Marc Kelliny, Paul E Croarkin, Katherine M Moore, William V Bobo Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA Abstract: This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-08-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/profile-of-vortioxetine-in-the-treatment-of-major-depressive-disorder--peer-reviewed-article-TCRM |
| _version_ | 1818925098889904128 |
|---|---|
| author | Kelliny M Croarkin PE Moore KM Bobo WV |
| author_facet | Kelliny M Croarkin PE Moore KM Bobo WV |
| author_sort | Kelliny M |
| collection | DOAJ |
| description | Marc Kelliny, Paul E Croarkin, Katherine M Moore, William V Bobo Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA Abstract: This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided. Keywords: vortioxetine, Lu AA21004, pharmacological profile, pharmacokinetics, drug interactions, adverse effects/side effects/safety, depression, major depression |
| first_indexed | 2024-12-20T02:35:50Z |
| format | Article |
| id | doaj.art-fa9d5c3386374ad78a50bb17f3cf9506 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-20T02:35:50Z |
| publishDate | 2015-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-fa9d5c3386374ad78a50bb17f3cf95062022-12-21T19:56:27ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2015-08-012015default1193121223143Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureKelliny MCroarkin PEMoore KMBobo WVMarc Kelliny, Paul E Croarkin, Katherine M Moore, William V Bobo Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA Abstract: This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided. Keywords: vortioxetine, Lu AA21004, pharmacological profile, pharmacokinetics, drug interactions, adverse effects/side effects/safety, depression, major depressionhttp://www.dovepress.com/profile-of-vortioxetine-in-the-treatment-of-major-depressive-disorder--peer-reviewed-article-TCRM |
| spellingShingle | Kelliny M Croarkin PE Moore KM Bobo WV Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature Therapeutics and Clinical Risk Management |
| title | Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature |
| title_full | Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature |
| title_fullStr | Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature |
| title_full_unstemmed | Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature |
| title_short | Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature |
| title_sort | profile of vortioxetine in the treatment of major depressive disorder an overview of the primary and secondary literature |
| url | http://www.dovepress.com/profile-of-vortioxetine-in-the-treatment-of-major-depressive-disorder--peer-reviewed-article-TCRM |
| work_keys_str_mv | AT kellinym profileofvortioxetineinthetreatmentofmajordepressivedisorderanoverviewoftheprimaryandsecondaryliterature AT croarkinpe profileofvortioxetineinthetreatmentofmajordepressivedisorderanoverviewoftheprimaryandsecondaryliterature AT moorekm profileofvortioxetineinthetreatmentofmajordepressivedisorderanoverviewoftheprimaryandsecondaryliterature AT bobowv profileofvortioxetineinthetreatmentofmajordepressivedisorderanoverviewoftheprimaryandsecondaryliterature |